iRGD肽协同奥沙利铂逆转结直肠肿瘤耐药的研究进展

结直肠癌是世界上常见的恶性肿瘤，奥沙利铂（oxaliplatin）是常用于结直肠肿瘤化疗的第三代铂类药物，以其为基础的化疗方案现已成为结直肠癌化疗的标准方案。结直肠癌化疗无效的一个重要原因是肿瘤细胞对化疗药物产生耐药，最近研究发现，具有靶向能力的修饰物与化疗药物结合，能提高肿瘤组织内化疗药物的局部浓度。iRGD肽作为一种靶向肽与化疗药物结合，能增强化疗效果，血管内注射与iRGD肽偶联修饰过的化疗药物，能导致化疗药物与肿瘤血管结合，并能扩散到血管外的肿瘤实质。本文就iRGD肽协同奥沙利铂逆转结直肠肿瘤耐药的研究进展做详尽综述。

Advances in research of iRGD peptide cooperating with oxaliplatin in reversing colorectal cancer drug resistance

Colorectal cancer is a common malignant tumor in the world. Oxaliplatin is the third-generation platinum drug and commonly used in colorectal cancer, its chemotherapy-based regimen has become the standard for chemotherapy for colorectal cancer. An important reason of colorectal cancer chemotherapy failure is the development of drug resistance of tumor cells to chemotherapy drugs. Recent studies have found that the combination of targeting modifiers and chemotherapeutic drugs can increase the local concentration of chemotherapeutic drugs in the tumor tissue. iRGD peptide, as a mediator in combination with chemotherapeutic drugs, potentiates the chemotherapeutic effect, intravascular injection of a chemotherapeutic drug modified with the iRGD peptide can cause the chemotherapeutic drug to bind to the tumor blood vessel and spread to the extravascular tumor mass. In this paper, advances in research of iRGD peptide cooperating with oxaliplatin in reversing colorectal cancer drug resistance are reviewed in detail.